Physician profile
Norman Weir
NPI 1033147772
$150.09
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.26 · 2020: $41.62 · 2022: $59.21.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $45.15 | 2022 | |
| Optinose US, INC. | $24.39 | 2020 | |
| Olympus America INC. | $19.81 | 2019 | |
| Pfizer INC. | $17.23 | 2020 | |
| Smith+Nephew, INC. | $16.45 | 2019 | |
| Medtronic, INC. | $14.06 | 2022 | |
| Intersect Ent, INC. | $13.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Weir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.